降糖西药治疗非酒精性脂肪性肝病并发2型糖尿病的研究进展  

Research progress in hypoglycemic agents for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus

作　　者：李海洋 熊媛琴 王景淑 艾耀伟 LI Hai-yang;XIONG Yuan-qin;WANG Jing-shu;AI Yao-wei(Medical College of China Three Gorges University,Yichang Hubei 443000;The First College of Clinical Medical Science,China Three Gorges University,Yichang Hubei 443000;Yichang Central People’s Hospital,Yichang Hubei 443000)

机构地区：[1]三峡大学医学院,湖北宜昌443000 [2]三峡大学第一临床医学院,湖北宜昌443000 [3]宜昌市中心人民医院,湖北宜昌443000

出　　处：《中南药学》2024年第6期1609-1614,共6页Central South Pharmacy

基　　金：湖北省卫生健康委员会联合基金项目(No.WJ2019H507);宜昌市医疗卫生研究项目(No.A20-2-023)。

摘　　要：非酒精性脂肪性肝病(NAFLD)和2型糖尿病(T2DM)在临床上都是常见病,常同时存在或互相影响疾病的发生发展,胰岛素抵抗(IR)可能是它们共同发病的关键机制。近年来,NAFLD的患病率逐年上升,已成为发病率第一的肝病。某些降糖药物除了能有效管理血糖,还能改善肝脏脂肪变性、气球样变、肝纤维化和炎症指标,可能是治疗NAFLD的潜在药物。现就二甲双胍、DPP-4抑制剂、GLP-1受体激动剂、SGLT-2抑制剂、PPAR激动剂在治疗NAFLD合并T2DM患者中的作用效果进行综述,以期为NAFLD后续的药物研究和临床治疗提供参考。Nonalcoholic fatty liver disease(NAFLD)and type 2 diabetes mellitus(T2DM)are both common.They often coexist or affect the occurrence and development of other diseases at the same time.Insulin resistance may be the key common pathogenesis.In recent years,the incidence rate of NAFLD has increased year by year.Current studies have shown that some hypoglycemic drugs can not only effectively manage blood glucose,but also improve liver steatosis,ballooning,liver fibrosis and inflammation indicators,which may be potential drugs for NAFLD.This article reviewed the effects of metformin,DPP-4 inhibitors,GLP-1 receptor agonists,SGLT-2 inhibitors,and PPAR agonists on NAFLD patients with T2DM,providing ideas for the treatment of NAFLD and reference for subsequent drug research.

关 键 词：非酒精性脂肪性肝病 2型糖尿病 降糖药物 SGLT-2抑制剂 

分 类 号：R587.2[医药卫生—内分泌] R575.5[医药卫生—内科学]